Skip to main
  1. Stocks
  2. AbbVie
  3. Forecast
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 30%
Buy 52%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is viewed favorably because its core immunology engine continues to compound, with 3Q26 sales up 10% year over year and Skyrizi and Rinvoq growing 23% and 24%, respectively, while management raised FY 2026 revenue guidance to about $67.8 billion and EPS to $13.95-$13.99. Its outlook is further strengthened by a clean patent runway to 2035+, strong cash generation, and durable franchises that appear to be taking roughly half of new patient starts in key categories, supporting margin leverage as scale builds. The portfolio is also becoming more diversified through the 2020 Allergan deal and the 2024 Cerevel and ImmunoGen acquisitions, while 2026 Apogee adds immunology depth and pipeline optionality.

Bears say

AbbVie is challenged by a deteriorating base business as operating margins come under pressure, EPS growth slows, and valuation could compress from the mid-teens multiple if growth weakens faster than expected. Its outlook is burdened by increasing competition in immunology that could erode Skyrizi and Rinvoq, along with patent challenges, negative pipeline data, and approval delays that threaten key growth drivers across immunology, oncology, and neuroscience. The company also faces material sustainability and execution risks, including government pricing pressure, supply-chain concentration, product-liability exposure, and $3.7 billion in upfront acquisition charges in nine months of 2025, while its Aesthetics business was ~8% of sales in FY 2025 and remains vulnerable to discretionary spending.

AbbVie (ABBV) has been analyzed by 23 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 52% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

AbbVie (ABBV) Analyst Forecast & Price Prediction

Get the latest AbbVie (ABBV) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AbbVie (ABBV)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 23 analysts, AbbVie (ABBV) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $302.74, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $302.74, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


AbbVie (ABBV) Analyst Forecast & Price Prediction

Get the latest AbbVie (ABBV) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AbbVie (ABBV)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ABBV stock data and trends